
Akebia Ther is a biotechnology business based in the US. Akebia Ther shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Akebia Ther employs 426 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Akebia Ther
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AKBA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Active traders

Akebia Ther stock price (NASDAQ: AKBA)
Use our graph to track the performance of AKBA stocks over time.Akebia Ther shares at a glance
Latest market close | $0.41 |
---|---|
52-week range | $0.30 - $3.71 |
50-day moving average | $0.39 |
200-day moving average | $1.83 |
Wall St. target price | $1.42 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.60 |
Buy Akebia Ther shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Akebia Ther stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Akebia Ther price performance over time
Historical closes compared with the close of $0.409 from 2022-07-05
1 week (2022-06-30) | 15.83% |
---|---|
1 month (2022-06-03) | N/A |
3 months (2022-04-07) | -24.47% |
6 months (2022-01-07) | -81.49% |
1 year (2021-07-07) | -87.90% |
---|---|
2 years (2020-07-07) | -96.86% |
3 years (2019-07-05) | 4.38 |
5 years (2017-07-07) | 14.21 |
Akebia Ther financials
Revenue TTM | $223 million |
---|---|
Gross profit TTM | $-17,922,000 |
Return on assets TTM | -26.12% |
Return on equity TTM | -229.73% |
Profit margin | -123.64% |
Book value | $0.14 |
Market capitalisation | $71.4 million |
TTM: trailing 12 months
Akebia Ther share dividends
We're not expecting Akebia Ther to pay a dividend over the next 12 months.
Akebia Ther share price volatility
Over the last 12 months, Akebia Ther's shares have ranged in value from as little as $0.3 up to $3.709. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Ther's is 1.5495. This would suggest that Akebia Ther's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Akebia Ther overview
Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd.
Akebia Ther in the news
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka
Frequently asked questions
What percentage of Akebia Ther is owned by insiders or institutions?Currently 1.509% of Akebia Ther shares are held by insiders and 49.606% by institutions. How many people work for Akebia Ther?
Latest data suggests 426 work at Akebia Ther. When does the fiscal year end for Akebia Ther?
Akebia Ther's fiscal year ends in December. Where is Akebia Ther based?
Akebia Ther's address is: 245 First Street, Cambridge, MA, United States, 02142 What is Akebia Ther's ISIN number?
Akebia Ther's international securities identification number is: US00972D1054 What is Akebia Ther's CUSIP number?
Akebia Ther's Committee on Uniform Securities Identification Procedures number is: 00972D105
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert